Literature DB >> 16606989

Varicella zoster virus meningitis complicating sodium stibogluconate treatment for cutaneous leishmaniasis.

Joshua D Hartzell1, Naomi E Aronson, Sudhir Nagaraja, Tim Whitman, Clifton A Hawkes, Glenn Wortmann.   

Abstract

Sodium stibogluconate (Pentostam(R); GlaxoSmithKline) is a pentavalent antimonial compound used in the treatment of leishmaniasis, which has an association with reactivation of varicella zoster virus (VZV). We report the first known case of an immunocompetent adult who developed VZV aseptic meningitis and dermatomal herpes zoster during treatment with sodium stibogluconate.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16606989

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  4 in total

1.  Urinary antimony and leukocyte telomere length: An analysis of NHANES 1999-2002.

Authors:  Franco Scinicariello; Melanie C Buser
Journal:  Environ Res       Date:  2016-07-15       Impact factor: 6.498

2.  Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected].

Authors:  Emily S Wise; Margaret S Armstrong; Julie Watson; Diana N Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2012-06-26

3.  Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds.

Authors:  Andrea Barbieri Barros; Alex Miranda Rodrigues; Mariane Pereira Batista; Sidney Munhoz Junior; Marcia Hueb; Cor Jesus Fontes
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-07-03       Impact factor: 2.743

4.  Ramsey hunt syndrome after antimonial treatment for American Cutaneous Leishmaniasis.

Authors:  Melissa de Sousa Melo Cavalcante; Karina López Rodríguez; José Alejandro Lazo Diéguez; Luciana Mendes Dos Santos; Maria das Graças Vale Barbosa Guerra; Jorge Augusto de Oliveira Guerra
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-13       Impact factor: 1.581
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.